泰加保險(06161.HK)主席轉換CB觸技術全購 周一復牌
泰加保險(06161.HK)公布,主席吳宇(作為要約人)建議轉換金額1.98億元的可換股債券,公司將按每股0.57元發行3.48億股。完成後,要約人於公司持股將由目前22.18695%增至49.99995%,須按例提出強制性無條件現金要約,每股作價0.57元,較停牌前折讓41.24%。
要約人無意將集團私有化,並擬維持股份於聯交所上市。
由於TICL為保險業條例項下的獲授權保險公司,建議轉換及提出要約須待保險業監管局作出所需確認、同意或批准後,方告作實。至今,先決條件並未達成。
公司股份申請周一(4日)恢復買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.